Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167777 | 0.84 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1148520 | 0.83 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL790160 | 0.82 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL10830752 | 0.82 | CA12 (0.40) | MEN1KMT2A | |
| SCHEMBL19025042 | 0.82 | FOLH1 (0.36) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16401965 | 0.81 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL4334790 | 0.81 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1149044 | 0.81 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL28997958 | 0.81 | KDM5A (0.44) | MEN1KMT2AKDM5A | |
| SCHEMBL28997023 | 0.81 | KDM5A (0.44) | MEN1KMT2AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385024-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2887963-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2887963-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029984-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | MEN1 4780/4885HTT 1823/4885KMT2A 3985/4885 |
| US-10385024-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP2 | MEN1 4780/4885HTT 1823/4885KMT2A 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.